AstraZeneca (AZN) Stock Forecast & Price Target

$78.40 +0.46 (+0.59%)

As of 03:11 PM Eastern

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 5 Analyst Ratings

Sell
0

Hold
1

Buy
4

Based on 5 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for AZN.

Consensus Price Target

$86.00
9.70% Upside

According to the 5 analysts' twelve-month price targets for AstraZeneca, the average price target is $86.00. The highest price target for AZN is $97.00, while the lowest price target for AZN is $75.00. The average price target represents a forecasted upside of 9.70% from the current price of $78.40.

Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

AZN Analyst Ratings Over Time

Type	Current Forecast 8/14/24 to 8/14/25	1 Month Ago 7/15/24 to 7/15/25	3 Months Ago 5/16/24 to 5/16/25	1 Year Ago 8/15/23 to 8/14/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	4 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$86.00	$89.00	$88.00	$89.75
Forecasted Upside	9.70% Upside	26.56% Upside	27.89% Upside	7.15% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca Stock vs. The Competition

Type	AstraZeneca	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	10.34% Upside	13,553.17% Upside	10.87% Upside
News Sentiment Rating	Positive News See Recent AZN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/9/2025	Berenberg Bank 2 of 5 stars	Luisa Hector Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$97.00	+37.02%
4/15/2025	BNP Paribas 4 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00	+11.09%
2/13/2025	UBS Group 4 of 5 stars	M. Weston Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy
2/12/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight
11/6/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
9/11/2024	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
8/12/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$90.00 ➝ $95.00	+16.29%
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$80.00 ➝ $85.00	+10.72%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$97.00	+27.50%
4/26/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$80.00 ➝ $82.00	+8.70%
1/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
12/18/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:11 PM ET.

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 12, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca:

The current stock price is around $74.84, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
AstraZeneca has shown a strong revenue growth of 16.1% compared to the same quarter last year, indicating robust business performance and potential for future profitability.
The company has a solid net margin of 14.68%, suggesting effective cost management and the ability to convert sales into actual profit.
AstraZeneca's return on equity stands at 32.84%, reflecting efficient use of shareholders' equity to generate profits, which is attractive for investors seeking high returns.
Analysts have a consensus rating of "Moderate Buy" for AstraZeneca, with several buy ratings and a price target of $89.00, indicating positive market sentiment towards the stock.

AstraZeneca
Bear Case

Investors should be bearish about investing in AstraZeneca for these reasons:

The company recently cut its dividend, which may signal financial strain or a shift in strategy that could concern income-focused investors.
AstraZeneca's stock has a relatively high price-to-earnings (P/E) ratio of 28.14, which may indicate that the stock is overvalued compared to its earnings, posing a risk for potential investors.
The stock has experienced volatility, with a 52-week range between $61.24 and $87.68, suggesting that it may not be a stable investment in the short term.
Institutional investors currently own 20.35% of the company's stock, which may limit the influence of retail investors and could lead to less favorable market movements.
Recent market conditions and economic uncertainties could impact AstraZeneca's performance, making it a riskier investment in the current climate.

AZN Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $86.00, with a high forecast of $97.00 and a low forecast of $75.00.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AZN shares.
: According to analysts, AstraZeneca's stock has a predicted upside of 9.70% based on their 12-month stock forecasts.
: AstraZeneca has been rated by research analysts at Berenberg Bank in the past 90 days.
: Analysts like AstraZeneca less than other "medical" companies. The consensus rating score for AstraZeneca is 2.80 while the average consensus rating score for "medical" companies is 2.81. Learn more on how AZN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:AZN) was last updated on 8/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Stock Forecast & Price Target